Zymeworks Net Income 2016-2021 | ZYME

Zymeworks net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Zymeworks Annual Net Income
(Millions of US $)
2020 $-181
2019 $-145
2018 $-37
2017 $-11
2016 $-34
2015 $-19
Zymeworks Quarterly Net Income
(Millions of US $)
2021-09-30 $-61
2021-06-30 $-68
2021-03-31 $-45
2020-12-31 $-38
2020-09-30 $-73
2020-06-30 $-39
2020-03-31 $-31
2019-12-31 $-72
2019-09-30 $-30
2019-06-30 $-29
2019-03-31 $-14
2018-12-31 $9
2018-09-30 $-19
2018-06-30 $-6
2018-03-31 $-21
2017-12-31 $33
2017-09-30 $-16
2017-06-30 $-11
2017-03-31 $-16
2016-12-31 $-11
2016-09-30 $-12
2016-06-30 $-7
2016-03-31 $-3
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.902B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95